[ad_1]
Biocon Ltd is leading India’s lead in weight loss drugs as the patents of some blockbuster drugs are about to expire.
The pharma company has won approval from the UK regulator for the first generic version of liraglutide injection, which lost patent protection in November.
Novo Nordisk’s weight-loss drug, sold under the brand name Saxenda, is one of the first anti-obesity drugs to lose patent protection.
Also read: Can weight loss drugs like Ozempic, Vegovy treat other diseases?
“My leadership team and the organization are ensuring that we do not give up our leadership position,” Biocon Chief Executive Officer (CEO) Siddharth Mittal said in an interview. bloomberg,
He also said another 15 peptide formulations are under development, of which one or two drugs will seek regulatory approval this year.
Biocon has also filed applications with US and European regulators for liraglutide.
The company has not yet applied for liraglutide approval in India.
anti obesity market
Many pharma companies are eager to enter the anti-obesity market, which is expected to reach $100 billion by 2030.
Saxenda is considered less effective for weight loss than Vegovy and Ozempic, but its generic version is the start of a jackpot that drugmakers like Biocon have been waiting for.
The patents on Ozempic and Vegovy will expire in the coming years, leaving cheaper copies of the drug on the market.
In the UK, Biocon will wait for the publicly funded National Health Services to issue a tender to launch its liraglutide injection, Mittal said. bloomberg Report.
Also read: Novo Nordisk pays $25.8 million to promote its obesity drug
Biocon had filed the UK application through its European partner Zentiva SA.
The total UK market opportunity for GLP-1 in diabetes and weight loss is $425 million, according to a March 27 statement from Biocon.
Indian drugmakers Sun Pharmaceutical Industries, Dr Reddy’s Laboratories and Cipla are also developing their own anti-obesity drugs.
Novo Nordisk, which sells its semaglutide-based pill Ribelsus in India, plans to introduce Vegovy and Ozempic in 2026, according to a reuters report in february
Eli Lilly is conducting clinical trials in the country for its weight loss pill orforgliprone.
Unlock a world of benefits! From informative newsletters to real-time stock tracking, breaking news and personalized newsfeeds – it’s all here, just a click away! log in now!
Catch all business news, market news, breaking news events and latest news updates on Live Mint. Download Mint News app to get daily market updates.
more less
Published: 08 April 2024, 04:54 PM IST
[ad_2]
